$377 Million is the total value of Opaleye Management Inc.'s 44 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TARA | New | ARTARA THERAPEUTICS INC | $52,142,000 | – | 2,208,472 | +100.0% | 13.82% | – |
| KALA | New | KALA PHARMACEUTICALS INC | $7,234,000 | – | 782,000 | +100.0% | 1.92% | – |
| MTEM | New | MOLECULAR TEMPLATES INC | $7,089,000 | – | 533,400 | +100.0% | 1.88% | – |
| MYOV | New | MYOVANT SCIENCES LTD | $4,953,000 | – | 656,000 | +100.0% | 1.31% | – |
| CPRX | New | CATALYST PHARMACEUTICALS INC | $4,043,000 | – | 1,050,000 | +100.0% | 1.07% | – |
| VSTM | New | VERASTEM INC | $3,865,000 | – | 1,463,900 | +100.0% | 1.02% | – |
| NERV | New | MINERVA NEUROSCIENCES INC | $2,710,000 | – | 450,100 | +100.0% | 0.72% | – |
| CDTX | New | CIDARA THERAPEUTICS INC | $2,247,000 | – | 906,056 | +100.0% | 0.60% | – |
| KALV | New | KALVISTA PHARMACEUTICALS INC | $1,721,000 | – | 225,000 | +100.0% | 0.46% | – |
| PRVB | New | PROVENTION BIO INC | $1,527,000 | – | 166,000 | +100.0% | 0.40% | – |
| SELB | New | SELECTA BIOSCIENCES INC | $940,000 | – | 390,000 | +100.0% | 0.25% | – |
| New | OCULAR THERAPEUTIX INCcall | $53,000 | – | 1,000 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-10 |
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
| SC 13G | 2024-04-08 |
| 4 | 2024-03-28 |
| 4 | 2024-03-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.